XML 55 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
Development, Commercialization and Supply Agreement - Additional Information (Detail)
 1 Months Ended 3 Months Ended
Sep. 30, 2017
USD ($)
Mar. 31, 2016
USD ($)
Feb. 28, 2015
USD ($)
Mar. 31, 2018
USD ($)
Item
Mar. 31, 2017
USD ($)
Dec. 31, 2017
USD ($)
License And Collaboration Agreements [Line Items]            
Licensing revenue       $ 142,000 $ 293,000  
Deferred revenue       $ 18,912,000   $ 19,054,000
Eddingpharm            
License And Collaboration Agreements [Line Items]            
Non-refundable up-front received     $ 15,000,000      
Number of indications of the regulatory milestone events relating to the submission and approval | Item       3    
Amounts to be received upon achievement of the regulatory milestone events       $ 33,000,000    
Sales-based milestone event payment       120,000,000    
Licensing revenue         300,000  
Licenses revenue to date       2,800,000   3,100,000
Deferred revenue       $ 13,200,000 12,900,000  
Revenue recognized over remaining period       16 years    
Eddingpharm | Maximum            
License And Collaboration Agreements [Line Items]            
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone       $ 153,000,000    
Amounts to be received upon achievement of the regulatory milestone events       15,000,000    
Sales-based milestone event payment       50,000,000    
Licensing revenue       100,000    
Eddingpharm | Minimum            
License And Collaboration Agreements [Line Items]            
Amounts to be received upon achievement of the regulatory milestone events       1,000,000    
Sales-based milestone event payment       5,000,000    
Eddingpharm | Clinical Trial Application            
License And Collaboration Agreements [Line Items]            
Non-refundable milestone payment   $ 1,000,000        
Biologix FZCo            
License And Collaboration Agreements [Line Items]            
Revenue recognition period of non-refundable up-front payment   10 years        
HLS            
License And Collaboration Agreements [Line Items]            
Non-refundable up-front received $ 5,000,000          
Licensing revenue       100,000 $ 0  
Licenses revenue to date       300,000   100,000
Deferred revenue       $ 4,700   $ 4,900
Revenue recognized over remaining period       12 years    
Non-refundable up-front received period 6 months          
HLS | Maximum            
License And Collaboration Agreements [Line Items]            
Additional upfront payment eligible to receive based on development, regulatory and sales Milestone $ 60,000,000